| Chemical Properties | Back Directory | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMF: 20 mg/mL,DMSO: 16 mg/mL,Ethanol: 16 mg/mL | [form ]
A solid | [pka]
12.00±0.70(Predicted) |
| Hazard Information | Back Directory | [Uses]
MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir.html" class="link-product" target="_blank">Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19[1]. | [Biological Activity]
(±)-MMT5-14 is a derivative of remdesivir with antiviral activity.1 It increases the viability of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50 = 0.4 μM), as well as Vero E6 cells infected with the Alpha, Beta, Gamma, or Delta SARS-CoV-2 variants (EC50s = 2.5, 15.9, 1.7, and 5.6 μM, respectively). (±)-MMT5-14 exhibits increased plasma and lung concentrations compared with remdesivir in hamsters when administered at a dose of 10 mg/kg. | [in vivo]
MMT5-14 (10 mg/kg; i.v. once) shows a higher stability than remdesivir in microsomes, and shows higher concentrations of prodrugs and active metabolites (NTP) in blood and lungs[1]. | Animal Model: | Catheterized female hamsters[1] | | Dosage: | 10 mg/kg | | Administration: | Intravenous injection; 10 mg/kg once | | Result: | Showed higher intact prodrugs concentration than remdesivir in lungs after 4 hours injection, increased tissue exposure in most of the tissues and showed 5- to 10-fold higher tissue selectivity in lungs compared to remdesivir. |
| [storage]
-20°C | [References]
1.Hu, H., Traore, M.D.M., Li, R., et al.Optimization of the prodrug moiety of remdesivir to improve lung exposure/selectivity and enhance anti-SARS-CoV-2 activityJ. Med. Chem.65(18)12044-12054(2022)
|
|
|